366
Participants
Start Date
October 11, 2018
Primary Completion Date
May 13, 2020
Study Completion Date
May 13, 2020
Blautix
Blautix is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen was two capsules two times per day for the duration of the treatment period.
Placebo
Placebo control
Capitol Research, Rockville
Blue Ridge Medical Research, Lynchburg
PharmQuest, Greensboro
Coastal Carolina Research Center, Mt. Pleasant
Georgia Medical Associates, Snellville
East Coast Institute for Research, LLC., Saint Augustine
Borland-Groover Clinic, Jacksonville
Orlando Florida BioClinica Research Network, Orlando
Clinical Research Center of Florida, Pompano Beach
Digestive CARE of North Broward, LLC, Coral Springs
Guardian Angel Research Center, Tampa
Clinical Research Associates, Huntsville
WR-ClinSearch, Chattanooga
Clinical Neuroscience Solutions, Inc, Memphis
Aventiv Research Inc., Columbus
Evanston Premier Healthcare & Research, LLC., Evanston
Specialists in Gastroenterology, St Louis
Centex Research, Inc., Lake Charles
Houston Methodist Gastroenterology Associates, Houston
Gulf Coast Medical Research, LLC., Missouri City
Elite Clinical Studies, Phoenix
Translational Research Group, Inc, North Hollywood
Probe Clinical Research, Riverside
Connecticut Gastroenterology Clinical Research, Bristol
Cork University Hospital, Cork
MAC Clinical Research (Barnsley), Barnsley
MAC Clinical Research (Blackpool), Blackpool
MAC Clinical Research (Cannock), Cannock
CPS Research, Glasgow
MAC Clinical Research (Leeds), Leeds
MAC Clinical Research (Liverpool), Liverpool
MAC Clinical Research (Manchester), Manchester
Wythenshawe Hospital, Manchester
MAC Clinical Research (Stockton-on-Tees), Stockton-on-Tees
4D pharma plc
INDUSTRY